TLR7/8 激动剂及相关产品
TLR7和TLR8都是与病毒感染引起的免疫反应相关的胞内受体。它们识别富含GU的短单链RNA，以及咪唑喹啉和核苷类似物等人工合成的小分子。TLR7/TLR8的信号通路依赖于MyD-88的活化、AP-1和IFN-α/β等转录因子入核，以及IRF7的磷酸化。IRF7磷酸化诱导ISRE的表达和I型干扰素基因的产生，而AP-1和IFN-α/β的激活导致细胞因子的释放。
TLR7/8 激动剂相关产品：
|
PRODUCT |
ORIGIN/DESCRIPTION |
GRADE* |
WORKING CONCENTRATION |
QTY |
CATALOG CODE |
|
TLR7 Agonists |
|||||
|
CL264 |
Adenine analog |
TLR2 – /TLR4 – |
50 ng – 10 µg/ml |
500 µg 5 mg |
tlrl-c264e tlrl-c264e-5 |
|
CL307 |
Hydroxyadenine spermine compound |
TLR2 – /TLR4 – |
5 ng – 1 µg/ml |
500 µg |
tlrl-c307 |
|
CL347 – AdiFectin™ |
Hydroxyadenine spermine compound |
TLR2 – /TLR4 – |
300 ng – 3 µg/ml |
500 µg |
tlrl-c347 |
|
CL401 |
PAM2C-conjugated hydroxyadenine compound |
TLR2 + /TLR4 – |
1 ng – 10 µg/ml |
500 µg |
tlrl-c401 |
|
CL401 VacciGrade™ |
Preclinical grade CL401 |
VacciGrade™ |
20 – 50 µg/mouse |
1 mg |
vac-c401-5 |
|
CL413 – Adilipoline™ |
PAM2CK4-conjugated hydroxyadenine compound |
TLR2 + /TLR4 – |
50 pg – 10 µg/ml |
500 µg |
tlrl-c413 |
|
TLR7 Agonists |
|||||
|
CL413 VacciGrade™ |
Preclinical grade CL413 |
VacciGrade™ |
20 – 50 µg/mouse |
5 mg |
vac-c413-5 |
|
CL531 |
PAM2CK4-conjugated hydroxyadenine compound |
TLR2 +/ TLR4 – |
5 pg – 10 µg/ml |
500 µg |
tlrl-c531 |
|
CL572 |
Monoacyl-ethyl-cystein hydroxyadenine compound |
TLR2 +/ TLR4 – |
0.5 ng – 1 µg/ml |
500 µg |
tlrl-c572 |
|
Gardiquimod™ |
Imidazoquinoline compound |
TLR2 -/ TLR4 – |
0.1 – 3 µg/ml |
500 µg 5 mg |
tlrl-gdqs tlrl-gdq-5 |
|
Imiquimod (R837) |
Imidazoquinoline compound |
TLR2 -/ TLR4 – |
1 – 5 µg/ml |
500 µg 5 mg |
tlrl-imqs tlrl-imq |
|
Imiquimod VacciGrade™ |
Preclinical grade Imiquimod |
TLR2 -/ TLR4 – |
10 – 100 µg/mouse |
5 mg |
vac-imq |
|
Loxoribine |
Guanosine analog |
TLR2 -/ TLR4 – |
1 mM (300 µg/ml) |
50 mg |
tlrl-lox |
|
TLR8 Agonists |
|||||
|
ORN06/LyoVec™ |
ssRNA with 6 UUGU repeats / LyoVec™ |
TLR2 -/ TLR4 – |
0.25 – 5 µg/ml |
4 x 25 µg |
tlrl-orn6 |
|
ssPolyU Naked |
RNA homopolymer |
TLR2 -/ TLR4 – |
1 – 10 µg/ml |
10 mg 10 x 10 mg |
tlrl-sspu tlrl-sspu-100 |
|
ssPolyU/LyoVec™ |
RNA homopolymer / LyoVec™ |
TLR2 -/ TLR4 – |
1 – 10 µg/ml |
4 x 25 µg |
tlrl-lpu |
|
ssRNA40/LyoVec™ |
HIV-1 LTR-derived ssRNA / LyoVec™ |
TLR2 -/ TLR4 – |
0.25 – 5 µg/ml |
4 x 25 µg |
tlrl-lrna40 |
|
ssRNA41/LyoVec™ |
ssRNA40 control / LyoVec™ |
TLR2 -/ TLR4 – |
0.25 – 5 µg/ml |
4 x 25 µg |
tlrl-lrna41 |
|
TL8-506 |
Benzoazepine analog |
TLR2 -/ TLR4 – |
10 – 100 ng/ml |
500 µg |
tlrl-tl8506 |
|
TLR7/8 Agonists |
|||||
|
CL075 |
Thiazoquinoline compound |
TLR2 -/ TLR4 – |
100 ng – 5 µg/ml |
500 µg 5 mg |
tlrl-c75 tlrl-c75-5 |
|
CL097 |
Imidazoquinoline compound |
TLR2 -/ TLR4 – |
50 ng – 5 µg/ml |
500 µg 5 mg |
tlrl-c97 tlrl-c97-5 |
|
Poly(dT) |
Thymidine homopolymer ODN (17 mer) |
TLR2 -/ TLR4 – |
10 µM |
100 nmol |
tlrl-pt17 |
|
R848 (resiquimod) |
Imidazoquinoline compound |
TLR2 -/ TLR4 – |
10 ng – 10 µg/ml |
500 µg 5 mg |
tlrl-r848 tlrl-r848-5 |
|
R848 VacciGrade™ |
Preclinical grade R848 |
VacciGrade™ |
10 – 100 µg/mouse |
5 mg |
vac-r848 |
更多详情请咨询Invivogen代理商-上海金畔生物